On May 20, according to the official website of the Center for Tobacco Products (CTP) of the US Food and Drug Administration (FDA), Dr. Bret Koplow has been appointed as the Acting Director of the Center for Tobacco Products.
Resume information indicates that Dr. Brett Koplow was appointed as Acting Director of the Center for Tobacco Products (CTP) at the Food and Drug Administration in May 2025. In this role, Dr. Coplow is responsible for ensuring that the CTP achieves its public health goals and puts into practice the center's vision and mission in implementing the Family Smoking Prevention and Tobacco Control Act.
According to Bloomberg, FDA Commissioner Marty Makary stated in an internal email that senior FDA official Bret Koplow will temporarily assume the position.
According to Koplow' s LinkedIn page, he has been working at the FDA since 2011. Within the agency, he has held various positions, most recently serving as a senior advisor to the FDA Commissioner.
In April, the United States Department of Health and Human Services (HHS), under the leadership of Robert Kennedy Jr., carried out a large-scale layoff, resulting in the dismissal of Brian King, who was the Director of the Center for Tobacco Products (CTP) at the time. In May, The Campaign for Tobacco-Free Kids announced on its official website that Brian King had been appointed as the Executive Vice President for the U.S. program, tasked with leading the organization's efforts at the federal, state, and local levels.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
